Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8033783 | 0.87 | ALDH1A1 (0.62) | ALDH1A1LMNAMAPTPOLBPKM | |
| SCHEMBL6666839 | 0.85 | LMNA (0.53) | ALDH1A1LMNAMAPTPOLBPKM | |
| SCHEMBL8021350 | 0.82 | ALDH1A1 (0.78) | ALDH1A1LMNAPOLBSLC6A2SLC6A3 | |
| SCHEMBL12526433 | 0.82 | LMNA (0.50) | ALDH1A1LMNAMAPTPOLBPKM | |
| SCHEMBL17486683 | 0.82 | ELANE (0.53) | ALDH1A1LMNAMAPTPOLBPKM | |
| SCHEMBL10286400 | 0.81 | LMNA (0.53) | ALDH1A1LMNAMAPTPOLBPKM | |
| SCHEMBL722902 | 0.81 | ALDH1A1 (0.60) | ALDH1A1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL4029716 | 0.81 | ELANE (0.65) | ALDH1A1ELANE | |
| SCHEMBL6667696 | 0.81 | LMNA (0.57) | ALDH1A1LMNAMAPTPOLBPKM | |
| SCHEMBL19543351 | 0.81 | LMNA (0.48) | ALDH1A1LMNAMAPTPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| CN-112920092-B | Prodrugs of glutamine analogues | 约翰霍普金斯大学 | 2024-04-26 | — | — | CN | disclosed |
| US-11926640-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-03-12 | — | — | US | disclosed |
| EP-3328827-B1 | PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3328827-B1 | PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-4188373-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | Captor Therapeutics S.A. (PL) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022029138-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2022-02-10 | — | — | WO | disclosed |
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2021-07-08 | — | — | US | disclosed |
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2021-07-08 | — | — | US | disclosed |
| CN-112920092-A | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-06-08 | — | — | CN | disclosed |
| US-8524691-B2 | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010019511-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-1472230-B1 | ANSAMYCINS HAVING IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES | CONFORMA THERAPEUTICS CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7465718-B2 | Ansamycins having improved pharmacological and biological properties | CONFORMA THERAPEUTICS CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-20050267122-A1 | Ansamycins having improved pharmacological and biological properties | Zhang, Lin | 2005-12-01 | — | — | US | disclosed |
| EP-1472230-A4 | ANSAMYCINS HAVING IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES | CONFORMA THERAPEUTIC CORP (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1472230-A2 | ANSAMYCINS HAVING IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES | Conforma Therapeutic Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066005-A2 | ANSAMYCINS HAVING IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES | CONFORMA THERAPEUTICS CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267122-A1 | Ansamycins having improved pharmacological and biological properties | NARS1, AAAS, ASNS | ALDH1A1 1372/4885LMNA 474/4885MAPT 1479/4885 |
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | ALDH1A1 1032/4885LMNA 4756/4885MAPT 3959/4885 |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | ALDH1A1 3493/4885LMNA 3377/4885MAPT 4414/4885 |
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | MMP2, PSME2, PSME1 | ALDH1A1 2024/4885LMNA 2945/4885MAPT 3551/4885 |
| US-11926640-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | ALDH1A1 929/4885LMNA 4727/4885MAPT 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.